Previous 10 | Next 10 |
3.0 mg, 3 times daily selected as dose for future clinical development SEATTLE and VANCOUVER, British Columbia , June 11, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced posi...
SEATTLE and VANCOUVER, British Columbia , June 3, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it enter...
The USPTO has granted Achieve Life Sciences (NASDAQ: ACHV ), a patent (No. 10,300,050) on succinate salt of cytisinicline and use thereof. More news on: Achieve Life Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SEATTLE and VANCOUVER, British Columbia , May 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the Unit...
Achieve Life Sciences, Inc. (ACHV) Q1 2019 Results Conference Call May 15, 2019 04:30 PM ET Company Participants Jaime Xinos - EVP, Commercial Rick Stewart - CEO Dr. Cindy Jacobs - Chief Medical Officer Conference Call Participants Michael Higgins - Ladenburg Thalmann Joh...
In its Q1 report , Achieve Life Sciences (NASDAQ: ACHV ) announces that topline results from the Phase 2b ORCA-1 trial evaluating smoking cessation med cytisinicline should be available by the end of next month. The last study visit by the last enrollee has taken place. More news o...
Achieve Life Sciences (NASDAQ: ACHV ): Q1 GAAP EPS of -$0.88 misses by $0.25 . More news on: Achieve Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SEATTLE and VANCOUVER, British Columbia , May 15, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on...
SEATTLE and VANCOUVER, British Columbia , May 7, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it w...
SEATTLE and VANCOUVER, British Columbia , April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the la...
News, Short Squeeze, Breakout and More Instantly...
Achieve Life Sciences Inc. Company Name:
ACHV Stock Symbol:
NASDAQ Market:
Achieve Life Sciences Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that...
SEATTLE and VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced that the c...